A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

NCT02382549 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped The study was terminated because of slow accruals.

Conditions

Melanoma

Interventions

DRUG: BRAF inhibitor
BIOLOGICAL: 6MHP
DRUG: MEK inhibitor

Sponsor

Craig L Slingluff, Jr

Collaborators

[object Object]